Lenalidomide Generic Med
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA) has issued a Limited Sources Justification for the procurement of Lenalidomide Generic Medication. This action, categorized as an Award Notice, is for an "Order >SAT" and identifies Exelan Pharmaceuticals, Inc. (via Biologics by McKesson) as the sole capable source due to the unique requirements of the Lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program. The purpose is to establish a reliable and continuous supply of this critical medication for treating various blood cancers.
Purpose & Scope
Lenalidomide is an oral immunomodulatory medication used to treat multiple myeloma, anemia in myelodysplastic syndromes, and certain types of lymphoma. The contract aims to ensure a consistent supply for the West Texas VA Healthcare System Pharmacy Service. The REMS program mandates specific certifications for prescribers and pharmacies to dispense the medication, significantly limiting eligible suppliers.
Contract Details
- Type: Limited Sources Justification for an Order >SAT (Award Notice)
- Agency: Veterans Affairs, 257-NETWORK CONTRACT OFFICE 17 (36C257)
- Product/Service Code: 6505 - Drugs And Biologicals
- Place of Performance: Big Spring, TX
- Estimated Period of Performance: Until September 30, 2026
- Set-Aside: None specified
- Published Date: February 5, 2026
Justification & Market Research
The justification, based on FAR Part 8.405-6, states that Exelan Pharmaceuticals, Inc., through its distributor Biologics by McKesson, is the only entity currently meeting the stringent REMS program requirements for the VA. Market research confirmed no other qualified sources or authorized distributors could meet these specific requirements. The document lists specific quantities and part numbers for various strengths of Lenalidomide.
Future Actions
The VA intends to research other generic Lenalidomide agents to foster competition in future procurements.
Contact Information
- Primary: Tommy Haire (Tommy.haire@va.gov)
- Secondary: Matt Lee (matthew.lee5@va.gov, 2103939281)